Li Y, Wang L, Chen F, Liao R, Li J, Cao X
Front Immunol. 2025; 16:1534078.
PMID: 40028338
PMC: 11868074.
DOI: 10.3389/fimmu.2025.1534078.
Dahl J, Weier A, Winter C, Hintze M, Rothhammer V, Tsaktanis T
Neurol Neuroimmunol Neuroinflamm. 2025; 12(2):e200374.
PMID: 39933126
PMC: 11839221.
DOI: 10.1212/NXI.0000000000200374.
Barbeau L, Beelen N, Savelkouls K, Keulers T, Wieten L, Rouschop K
PLoS One. 2025; 20(2):e0316716.
PMID: 39928678
PMC: 11809862.
DOI: 10.1371/journal.pone.0316716.
Biedka S, Yablonska S, Peng X, Alkam D, Hartoyo M, VanEvery H
J Proteome Res. 2025; 24(2):795-812.
PMID: 39814365
PMC: 11812086.
DOI: 10.1021/acs.jproteome.4c00837.
Wen M, Zheng Q, Ji X, Xin S, Zhou Y, Tian Y
J Thorac Dis. 2024; 16(11):7999-8013.
PMID: 39678870
PMC: 11635230.
DOI: 10.21037/jtd-24-1058.
Assessing the 9G Technology Blood Test for Predicting Lung Cancer in Patients with CT-Detected Lung Nodules: A Multicenter Clinical Trial.
Kim S, Park Y, Kim I, Kim H, Lee K
Cancers (Basel). 2024; 16(22).
PMID: 39594693
PMC: 11593157.
DOI: 10.3390/cancers16223737.
Anti-PD-1 Autoantibody Predicts Survival of Patients With Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab.
Sasaki Y, Matsumoto K, Takaki A, Adachi T, Takahara M, Ozato K
Gastro Hep Adv. 2024; 3(8):1138-1147.
PMID: 39559295
PMC: 11570718.
DOI: 10.1016/j.gastha.2024.07.018.
Repertoires and Tumor-Reactivity Analysis of B Cell Immunoglobulins Derived from Cancer Patients.
Stoler-Barak L, Sarusi-Portuguez A, Shulman Z
Methods Mol Biol. 2024; 2864:263-279.
PMID: 39527227
DOI: 10.1007/978-1-0716-4184-2_14.
Emerging immunologic approaches as cancer anti-angiogenic therapies.
Azimi M, Manavi M, Afshinpour M, Khorram R, Vafadar R, Rezaei-Tazangi F
Clin Transl Oncol. 2024; .
PMID: 39294514
DOI: 10.1007/s12094-024-03667-2.
Autoantibodies in cancer: a systematic review of their clinical role in the most prevalent cancers.
Montero-Calle A, Garranzo-Asensio M, Moreno-Casbas M, Campuzano S, Barderas R
Front Immunol. 2024; 15:1455602.
PMID: 39234247
PMC: 11371560.
DOI: 10.3389/fimmu.2024.1455602.
Identification of autoantibodies as potential non-invasive biomarkers for intrahepatic cholangiocarcinoma.
Kajornsrichon W, Chaisaingmongkol J, Pomyen Y, Tit-Oon P, Wang X, Ruchirawat M
Sci Rep. 2024; 14(1):20012.
PMID: 39198554
PMC: 11358490.
DOI: 10.1038/s41598-024-70595-0.
Enhanced Lung Cancer Detection Using a Combined Ratio of Antigen-Autoantibody Immune Complexes against CYFRA 21-1 and p53.
Kim H, Lee J, Kim H, Hong Y
Cancers (Basel). 2024; 16(15).
PMID: 39123389
PMC: 11312164.
DOI: 10.3390/cancers16152661.
Characterization of latently infected EBV+ antibody-secreting B cells isolated from ovarian tumors and malignant ascites.
Zhang L, Strange M, Elishaev E, Zaidi S, Modugno F, Radolec M
Front Immunol. 2024; 15:1379175.
PMID: 39086481
PMC: 11288875.
DOI: 10.3389/fimmu.2024.1379175.
Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma.
Borgers J, van Wesemael T, Gelderman K, Rispens T, Verdegaal E, Moes D
J Immunother Cancer. 2024; 12(6).
PMID: 38945553
PMC: 11216046.
DOI: 10.1136/jitc-2024-009215.
Anti-BIRC5 autoantibody serves as a valuable biomarker for diagnosing AFP-negative hepatocellular carcinoma.
Li Q, Liu H, Wang H, Xiong W, Dai L, Zhang X
PeerJ. 2024; 12:e17494.
PMID: 38832035
PMC: 11146321.
DOI: 10.7717/peerj.17494.
Clinical Significance of Uncommon, Non-Clinical, and Novel Autoantibodies.
Shurin M, Wheeler S
Immunotargets Ther. 2024; 13:215-234.
PMID: 38686351
PMC: 11057673.
DOI: 10.2147/ITT.S450184.
Serum anti-CFL1, anti-EZR, and anti-CYPA autoantibody as diagnostic markers in ovarian cancer.
Cheng Y, Li Q, Sun G, Li T, Zou Y, Ye H
Sci Rep. 2024; 14(1):9757.
PMID: 38684875
PMC: 11058243.
DOI: 10.1038/s41598-024-60544-2.
Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations.
Casagrande S, Sopetto G, Bertalot G, Bortolotti R, Racanelli V, Caffo O
Cancers (Basel). 2024; 16(7).
PMID: 38611115
PMC: 11011060.
DOI: 10.3390/cancers16071440.
Harnessing the potential of long non-coding RNAs in breast cancer: from etiology to treatment resistance and clinical applications.
Wang Y, Bu N, Luan X, Song Q, Ma B, Hao W
Front Oncol. 2024; 14:1337579.
PMID: 38505593
PMC: 10949897.
DOI: 10.3389/fonc.2024.1337579.
Autoimmune Encephalitis with Antibodies Against A-Amino-3hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor and γ-Aminobutyric Acid-Beta Receptor: Case Report.
Dogan F, Samanci B, Yilmaz V, Hanagasi H, Gurvit I, Tuzun E
Noro Psikiyatr Ars. 2024; 61(1):94-96.
PMID: 38496216
PMC: 10943937.
DOI: 10.29399/npa.28388.